Leber’s hereditary optic neuropathy (LHON) is a rare, maternally inherited disorder that results in bilateral loss of central vision. Characteristic visual field defects in LHON consist of either central or cecocentral scotomas, with about 70% of the patients being young adult men. More than 90% of these patients carry 1 of 3 mitochondrial DNA (mtDNA) mutations, located at nucleotide positions 3460, 11778, or 14484, respectively, although >20 mtDNA point mutations have been reported in LHON patients worldwide. Retinal ganglion cells decrease by apoptosis, and finally the retinal nerve fiber thins (Read more...)
Long-term Safety of Ranibizumab in Neovascular Age-related Macular Degeneration
We read with interest the study from Silva et al on the long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration (nAMD). It described visual outcomes, drug tolerability, and safety of ranibizumab (Lucentis; Novartis Pharm…
Voriconazole for Fungal Keratitis
In their recently published trial, Sharma et al found topical voriconazole to be more effective than intrastromal voriconazole when added to topical natamycin in patients with recalcitrant fungal keratitis. This trial shares a similar protocol with se…
Change in Prostaglandin Expression Levels and Synthesizing Activities
We read with great interest the recently published study by Shim et al, which the authors described as a cross-sectional, case-control, clinical trial. As a single study, such a design is not possible because cross-sectional, case-control, and clinica…
Two Year SAVE Outcomes: 2.0 mg Ranibizumab for Recalcitrant Neovascular AMD
The Super-dose Anti-VEGF (SAVE) trial assessed the efficacy of 2.0 mg ranibizumab (0.05 ml), a 4-fold higher dose than the 0.5 mg dose approved by the US Food and Drug Administration, for the management of recalcitrant neovascular age-related macular d…
Author reply
We thank Prajna et al for their comments on our article titled, “Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis.” At the time of our publication, 1 study had been publ…